Michele Libonati

Michele brings over 30 years of experience in global management positions in the biotech and
pharmaceutical industry, primarily focused in the areas of neurodegeneration and demyelinating diseases,
spanning roles in CNS discovery research, CNS clinical development and commercialization, as well as
cross-functional strategic leadership roles where she was accountable for all aspects of product
management, including manufacturing.
Most recently she was founding CEO of Proneurotech, Inc., a privately held biopharmaceutical start-up
focused on discovering and developing neuroprotective drugs that prevent axon loss after acute injury or
chronic degenerative disease. Prior to Proneurotech she was with Genentech for 12 years, where she served
as Lifecycle Leader, Global Product Strategy, leading neurology, ophthalmology and immunology product
strategy and global commercialization. In these roles, she oversaw the successful development and
commercialization of a number of innovative flagship products, including OCREVUS®, the first anti-CD20
monoclonal antibody approved for patients with relapsing or primary progressive forms of multiple sclerosis
and the biggest product launch in the history of Genentech/Roche, achieving global sales of >1 billion CHF
within the first 10 months of launch, the development and launch of a number of ophthalmology line
extensions for LUCENTIS® and autoimmune indications for Rituxan®. During her tenure at Genentech, she
contributed to a substantial investment into immunology and neurology R&D that generated significant ROIs
through her leadership of several large product launches in these therapeutic areas.
Prior to Genentech she held global clinical development leadership positions with Elan Pharmaceuticals, Inc.
where she developed TYSABRI® for multiple sclerosis and other autoimmune diseases, including
inflammatory bowel disease (Crohn’s Disease and ulcerative colitis) and rheumatoid arthritis, and spent
several years working in start-up companies Somatix Therapy Corporation developing gene therapy
applications for the treatment of Parkinson’s disease and Alzheimer’s disease and Transcept
Pharmaceuticals, developing Intermezzo®, a treatment for insomnia.
Michele started the first ten years of her career working in neurology and psychiatric small molecule
discovery research and clinical development at Schering-Plough Research Institute, focused on treatments
for neurodegenerative diseases, epilepsy and schizophrenia. Michele received her B.A. from Rutgers
University and her M.S. in Pharmacology from New York Medical College.